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Abstract
Background: PCBP1 (or alpha CP1 or hnRNP E1), a member of the PCBP family, is widely expressed in many human 
tissues and involved in regulation of transcription, transportation process, and function of RNA molecules. However, 
the role of PCBP1 in CD44 variants splicing still remains elusive.
Results: We found that enforced PCBP1 expression inhibited CD44 variants expression including v3, v5, v6, v8, and v10 
in HepG2 cells, and knockdown of endogenous PCBP1 induced these variants splicing. Invasion assay suggested that 
PCBP1 played a negative role in tumor invasion and re-expression of v6 partly reversed the inhibition effect by PCBP1. A 
correlation of PCBP1 down-regulation and v6 up-regulation was detected in primary HCC tissues.
Conclusions: We first characterized PCBP1 as a negative regulator of CD44 variants splicing in HepG2 cells, and loss of 
PCBP1 in human hepatic tumor contributes to the formation of a metastatic phenotype.
Background
Alternative pre-mRNA splicing is emerging as an impor-
tant mechanism of genetic diversity. Microarray data
show that 74% of human genes undergo alternative splic-
ing, which generates different protein isoforms. Alterna-
tive splicing of several genes has been implicated in
tumorigenesis and tumor progression. The best known
example of these genes encodes the cell surface molecule
CD44.
CD44 is a transmembrane glycoprotein that mediates
the response of cells to their cellular microenvironment.
CD44 is expressed in most tissues, where its gene prod-
ucts function in lymphocyte homing, adhesion, migra-
tion, and regulation of cell growth [1]. Several functions
have been ascribed to some CD44 isoforms. The protein
domain coded by exon v3 has been shown to bind growth
factors via its heparan sulfate modifications [2], and
CD44 v4 is a major E-selection ligand that mediates
breast cancer cell transendothelial migration [3]. The
variant isoform CD44 v6 has attracted increasing interest
since the demonstration 1 decade ago that the transfec-
tion of splice variant CD44 v4-v7 conferred metastatic
potential on cells of a nonmetastatic rat tumor cell line
[4]. The CD44 v6 isoform can form a complex with the
extracellular hepatocyte growth factor (HGF) and its
tyrosine kinase receptor Met [5]. Formation of this CD44
v6-HGF-Met complex stimulates the activation of Met
through autophosphorylation and further activates Met-
dependent Ras signalling. The net result is that the CD44
v6-HGF-Met complex activates Ras signalling and pro-
motes cell proliferation. Interestingly, Ras activation also
stimulates transcription of CD44 and promotes inclusion
of its variable exons [6]. This constitutes a CD44-medi-
ated positive feedback loop in the activation of Ras sig-
nalling if a factor such as HGF is present. The tumor
suppressor merlin can bind to the cytoplasmic tail of
CD44 [7] and disrupts the interaction between ERM and
CD44 and therefore inhibits Ras activation. As a result,
Ras-dependent CD44 alternative splicing is inhibited, the
positive feedback loop is disrupted, and cell growth
diminishes [8]. These results raised the possibility that
CD44v acts as a prognostic factor of tumor progression
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and inhibition of CD44 v6 production may be a therapeu-
tic approach of tumor metastasis.
PCBPs are ubiquitously expressed and contain a highly
conserved triple repeat of the KH domain. Current data
clearly demonstrates that these proteins play important
and diverse roles in gene expression at both transcrip-
tional and posttranscriptional levels. PCBP1 (or αCP1 or
hnRNP E1), a member of the PCBPs family [9], is widely
expressed in many human tissues and involved in regula-
tion of transcription, transportation process, and func-
tion of RNA molecules [10]. Moreover, PCBP1 also has
been suggested to play a critical role in mRNA splicing. A
previous study reported that specific binding of PCBP1 to
U1 small nuclear ribonucleoprotein (snRNP) in the pre-
spliceosomal complex was associated with silencing of
pseudoexon splicing of growth hormone receptor.
Another hnRNP family member hnRNP A1 was a com-
ponent of an exon-specific splice-silencing complex, and
transient overexpression of hnRNP A1 prevented
CD44v5 splicing. However, the role of PCBP1 in CD44
variants splicing still remains elusive.
In the present study, we provide convincing evidence
that human PCBP1 regulates CD44 alternative splicing in
human hepatoma cell line HepG2 cells, and loss of
PCBP1 in human hepatic tumor may contribute to the
formation of a metastatic phenotype.
Results
PCBP1 negatively regulates CD44 variants
To investigate whether PCBP1 regulates CD44 variants,
HepG2 cells were transfected with pcDNA3.1(His/Myc)-
PCBP1 or control vector. A GFP-expression plasmid was
cotransfected either with the PCBP1 expressing vector or
control vector and all of the transfections displayed a sim-
ilar efficiency of about 45-48% (data not shown). At 24
hrs after transfection, the levels of CD44 variants were
monitored by RT-PCR using the primers described as
previously [11] and indicated as Figure 1A. In addition,
the CD44 standard form was detected using primers that
base-pair to the constitutive exons. The expression pro-
file of CD44 variants in HepG2 cells was shown in Figure
1B. As Figure 1C shows, enforced expression of PCBP1 in
HepG2 cells resulted in significant down-regulation of v2,
v3, v6, v7, v8, and v10 expression. In contrast, the levels of
CD44 v9 and standard form (std) were not affected by
overexpression of PCBP1.
To study the effect of endogenous PCBP1 on regulating
CD44 alternative splicing, we performed RNA interfer-
ence assays to investigate whether decreased PCBP1
expression altered CD44 variants expression. To rule out
off-target effects, two siRNA oligos were used (siPCBP1-
1 and siPCBP1-2). Transfection of HepG2 cells with
siPCBP1-1 or siPCBP1-2 resulted in an up to 77% or 44%
decrease in the PCBP1 mRNA level (Figure 1D upper
panel) and 72% or 58% decrease in the PCBP1 protein
level (Figure 1D, bottom panel) within 48 h after transfec-
tion. However, transfection with negative control RNA
(N.C) had no effect on PCBP1 protein and mRNA level.
Furthermore, the levels of β-actin were not affected by
negative control siRNAs (Figure 1D). As shown in Figure
1E, when endogenous PCBP1 expression was knocked
down by siRNAs, HepG2 cells showed an increased
e x p r e s s i o n  o f  C D 4 4  v a r i a n t s  c o m p a r e d  t o  t h e  c o n t r o l
cells. To rule out a possible non-specific effect of the neg-
ative control siRNA, another negative control siRNA
duplex (N.C-2) was used. The similar results were
obtained (Figure S1; Additional file 1). So we used N.C as
control in the following RNAi experiments. Overall, these
results indicated that PCBP1 might play a key role in the
regulation of CD44 alternative splicing in HepG2 cells.
We further investigated the role of PCBP1 in the regu-
lation of CD44 v5 expression. Since no specific band was
amplified using the present primer pair, we used a CD44
v5 reporter minigene construct pETCatEBLucv5 as
described previously [12] (Figure 2A). The
pETCatEBLucv5 vector was cotransfected into HepG2
cells with different doses of pcDNA3.1(His/Myc)-PCBP1
indicated as Figure 2B, and a Rennila luciferase plasmid
was served as an internal transfection control. As Figure
2C shows, PCBP1 overexpression reduced the level of
luciferase in a dose-dependent manner. The similar result
was obtained by RT-PCR analysis (Figure 2D). Consis-
tently, transient transfection of the PCBP1 siRNA pro-
duced an about 2-fold increase of relative luciferase
activity (Figure 2E). These results were verified by mea-
suring mRNA levels of v5 inclusion versus exclusion by
RT-PCR (Figure 2F).
PCBP1 inhibits the CD44 v6 expression
We further investigated the role of PCBP1 in the regula-
tion of CD44 v6 splicing in more detail. HepG2 cells were
transfected with different doses of PCBP1 expression vec-
tor, and 24 hours later total RNA was extracted for RT-
PCR and Real-time PCR analysis. As shown in Figure 3A-
B, transiently transfection with increasing amounts of
PCBP1 expression vector led to inhibition of CD44 v6
expression in a dose-dependent manner. Moreover, we
performed RNA interference assays as described above,
and the results suggested that knockdown of endogenous
PCBP1 resulted in significant induction of CD44 v6
expression (Figure 3C-D). To confirm the inhibition of
CD44 v6 expression by PCBP1, we performed the assays
in another hepatocellular carcinoma cell line SMMC-
7721 cells and the similar results were obtained (Figure
S2; Additional file 1).
We next detected whether PCBP1 inhibits the stimula-
tion of CD44 v6 by Ras/MAPK signalling. A constitu-
tively activated mutant H-Ras V12 construct was co-Zhang et al. Molecular Cancer 2010, 9:72
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transfected along with PCBP1 expression vector. As
shown in Figure 3E-F, transfection of H-Ras V12 resulted
in an approximately 1.6-fold upregulation of CD44 v6
mRNA compared to the control cells. However, co-trans-
fection with PCBP1 expression vector decreased the
CD44 v6 expression to basal level.
We further examined whether PCBP1 inhibits the stim-
ulation of CD44 v6 by HGF. HepG2 cells were transfected
with control vector or PCBP1 expression vector, and then
stimulated with 20 ng/ml HGF for 8 hours. Total RNA
were extracted and RT-PCR or Real-time PCR was per-
formed to detect the mRNA level of CD44 v6. As shown
in Figure 3G-H, HGF treatment led to about 2.2-fold
increase of v6 expression, while overexpression of PCBP1
inhibited the v6 expression significantly. These results
Figure 1 PCBP1 represses CD44 variants splicing. (A) Schematic diagram of the primers. (B) Expression profile of CD44 variants in HepG2 cells. (C) 
pcDNA3.1(His/Myc)-PCBP1 or control vector were transfected into HepG2 cells for 24 hours and total RNA were extracted for semi-quantitative RT-
PCR using the primers indicated in (A). The PCR bands were scanned for densitometry analysis with the value obtained from control cells set as 1. The 
values were normalized with those of GAPDH. Statistical analysis was performed and the results represented mean ± SD of 3 independent experi-
ments. The statistical difference between the samples was demonstrated as *p ≤ 0.05 and ** p ≤ 0.001 (D). (E) Knockdown of PCBP1. HepG2 cells were 
transfected with a negative control siRNA (N.C) or PCBP1 specific siRNA oligos (siPCBP1-1 and siPCBP1-2) for 48 hours. The level of PCBP1 was exam-
ined by Real-time PCR analysis (upper panel) and Western blotting (bottom panel). Cells with mock transfection were used as control (normal). For 
Real-time PCR, GAPDH was used as internal control. For Western blotting, the blots were scanned for densitometry analysis with the value obtained 
from control cells set as 1. The values were normalized with those of Actin. Statistical analysis was performed and the results represented mean ± SD 
of 3 independent experiments. (F). The levels of CD44 variants were examined by semi-quantitative RT-PCR (G). The PCR bands were scanned for den-
sitometry analysis with the value obtained from N.C cells set as 1 (H).Zhang et al. Molecular Cancer 2010, 9:72
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confirmed that PCBP1 is an important negative regulator
of CD44 v6 expression.
PCBP1 inhibits HepG2 cell invasion
CD44 v6 have been implicated in tumor invasion and
metastasis. Therefore, it is tempting to speculate that the
activity of PCBP1 could influence tumor cell invasion by
regulating the CD44 v6 expression. We first investigated
whether inhibition of CD44 v6 by RNA interference
would affect the invasive properties of HepG2 cells. A
siRNA direct against v6 exon was transfected into HepG2
cells. As shown in Figure 4A-B, we observed a significant
knockdown of v6 in cells treated with v6 siRNA. At 48 h
posttransfection, equal numbers of cells treated with
either v6 siRNA or control siRNA were added to invasion
chambers. After 24 hours of incubation, the cells that
invaded through the matrigel membrane and accumu-
lated in the lower chamber were counted. As expected,
the number of v6 siRNA-treated cells passing through the
membrane was only approximately 35% of the control
siRNA-treated cells. We observed similar results when
the above-described experiments were repeated using a
second v6 siRNA (data not shown). These results demon-
strated that CD44 v6 expression plays a key role in
HepG2 cell invasion.
To detect the effect of PCBP1 in cell invasion, PCBP1
expression vector or control vector was transfected into
HepG2 cells and cell invasion was measured. The number
of PCBP1 transfected cells passing through the mem-
brane was only approximately 55% of the control cells
(Figure 4C-D). However, knockdown of PCBP1 in HepG2
cells led to about 2.4-fold increased in the number of cells
passing through the membrane. These results suggested
that PCBP1 was involved in regulation of HepG2 cell
invasion. The similar results were obtained in SMMC-
7721 cells (Figure S3; Additional file 1).
Figure 2 PCBP1 inhibits CD44 v5 splicing. (A) Schematic representation of the luciferase splice reporter construct pETCatEBLucv5. (B) The 
pETCatEBLucv5 vector was cotransfected in HepG2 cells with different doses of pcDNA3.1(His/Myc)-PCBP1 vector and a Rennila luciferase plasmid 
served as an internal transfection control. The expression of overexpressed PCBP1 and endogenous PCBP1 was investigated by Western blotting. The 
blots were scanned for densitometry analysis with the value obtained from control cells set as 1. The values were normalized with those of Actin. The 
overexpressed PCBP1 levels were quantified relative to the endogenous PCBP1 expression level. 24 hours later cell lysis were prepared for the lu-
ciferase activity assay (C) and total RNA were extracted for RT-PCR (D). The level of luciferase was normalized to 100 following transfection with the 
control plasmid. The inclusion and exclusion fragments were produced by the primers indicated in (A). Values for exon inclusion were indicated. (E) 
HepG2 cells were co-transfected with pETCatEBLucv5 vector along with either negative control siRNA (N.C) or PCBP1 specific siRNA oligos for 48 hours 
and then luciferase activity was measured and the inclusion and exclusion fragments were analyzed by RT-PCR (F). Statistical analysis was performed 
and the results represented mean ± SD of 3 independent experiments. The statistical difference between the samples was demonstrated as ** p ≤ 
0.001.Zhang et al. Molecular Cancer 2010, 9:72
http://www.molecular-cancer.com/content/9/1/72
Page 5 of 10
We further investigated the relationship of PCBP1 and
v6 on tumor cell invasion. HepG2 cells were cotrans-
fected with PCBP1 expression vector and a Ras expres-
sion vector or a CD44 v6 expression construct. As shown
in Figure 4C-D, overexpression of Ras or v6 expression
vector led a significant increase of v6 expression (data not
shown) and cell invasion (Figure 4C-D). Cells transfected
with Ras or v6 expression vector showed about 4.2-fold or
3.1-fold increase of cell invasion respectively. Further-
more, re-expression of CD44 v6 by Ras activation or v6
Figure 3 PCBP1 is a negative regulator of CD44 v6. (A) Different doses of PCBP1 expression vector as indicated were transfected into HepG2 cells. 
Cells were harvested 24 hours later and total RNA were extracted for semi-quantitative RT-PCR and Real-time PCR analysis (B) to determine the relative 
amounts of CD44 v6. (C) HepG2 cells were transfected with a negative control siRNA (N.C) or PCBP1 specific siRNA oligos for 48 hours and then total 
RNA were extracted. The mRNA level of v6 was examined by semi-quantitative RT-PCR and Real-time PCR analysis (D). (E) PCBP1 inhibits the up-reg-
ulation of CD44 v6 induced by Ras activation. HepG2 cells were transfected with a constitutively activated mutant H-Ras V12 construct along with 
PCBP1 expression vector just as indicated. 24 hours later, total RNA were extracted for semi-quantitative PCR and Real-time PCR analysis (F). (G-H) 
PCBP1 inhibits the upregulation of CD44 v6 induced by HGF. HepG2 cells were transfected with control vector or PCBP1 expression vector, and then 
24 hours later the cells were stimulated with 20 ng/ml HGF for 8 hours. Total RNA was extracted and RT-PCR (G) or Real-time PCR (H) was performed 
to detect the level of CD44 v6. All the PCR bands were scanned for densitometry analysis with the value obtained from control cells set as 1. The values 
were normalized with those of GAPDH. Results represented mean ± SD of 3 independent experiments. The statistical difference between the samples 
was demonstrated as * p ≤ 0.05 or ** p ≤ 0.001.Zhang et al. Molecular Cancer 2010, 9:72
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expression vector in cells transfected with PCBP1 attenu-
ated the inhibition of cell invasion by PCBP1. Ras activa-
tion in PCBP1-transfected cells led to about 1.8-fold
increase of cell invasion while v6 expression vector
reversed the inhibition of cell invasion by PCBP1 to a
level similar to the control. These results suggested that
PCBP1 could play an important role in tumor cell inva-
sion by altering the level of CD44 v6 in HepG2 cells.
Up-regulation of CD44 v6 expression is accompanied by 
down-regulation of PCBP1 in HCC
Since PCBP1 was a negative regulator of CD44 v6 expres-
sion and tumor invasion, we further examined whether a
correlation of the expression status of PCBP1 and CD44
v6 exists in primary HCCs. Real-time PCR analysis was
performed to detect the mRNA levels of PCBP1 and
CD44 v6 in HCC tissue and the adjacent non-cancerous
liver tissues of 33 HCC patients. The result suggested that
in HCC tissues, PCBP1 showed significant negative cor-
relation with the expression of v6 (n = 33, r = -0.74689 p <
0.0001) (Figure 5A), that is, in HCC patients which
PCBP1 was down-regulated compared to the non-can-
cerous liver tissue, the CD44 v6 expression level showed a
significant up-regulation. However, no significant corre-
lation was detected between PCBP1 expression and
CD44 std expression in HCC (n = 24, r = 0.20696, p =
0.3319) (Figure 5B). These data suggested that the reduc-
tion of PCBP1 expression correlated with the up-regula-
tion of CD44 v6 expression in HCC.
Discussion
In the present study, we first characterized PCBP1 as a
novel negative regulator of CD44 variants splicing. Ecto-
pic expression of PCBP1 inhibits tumor invasion and
knockdown of endogenous PCBP1 expression stimulates
invasion, suggesting a negative role of PCBP1 in tumor
metastasis.
Alternative pre-mRNA splicing is controlled by coordi-
nate regulation between positive and negative factors.
Various studies suggest that alternative splicing can be
regulated by both cis-acting RNA elements, such as
exonic splicing enhancers (ESEs) and exonic splicing
silencers (ESSs), and trans-acting factors that can bind to
RNA elements directly. Two groups of proteins have been
found that can affect splice site choice: serine/arginine-
Figure 4 Negative role of PCBP1 in tumor cell invasion. (A) Invasion assays of HepG2 cell transfected with negative control siRNA (N.C) or siPCBP1-
1 or siv6-1. Quantitation of tumor cell invasion was described in (B). The percentage of cell invasion was normalized to that of cells transfected with 
control vector. (C) HepG2 cells were transfected with the vectors just as indicated for 24 hours and cell invasion assay was performed. Quantitation of 
tumor cell invasion was described in (D). The data are mean ± SD of at least three independent studies, each performed in triplicate. The statistical 
difference between the samples was demonstrated as * p ≤ 0.05 or ** p ≤ 0.001.Zhang et al. Molecular Cancer 2010, 9:72
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rich (SR) proteins and heterogeneous nuclear ribonucleo-
proteins (hnRNPs) [13]. ESEs are often bound by SR pro-
teins whereas exonic splicing silencers ESSs are typically
bound by hnRNP proteins [14]. A previous study report
that specific binding of PCBP1 to U1 small nuclear ribo-
nucleoprotein (snRNP) in the pre-spliceosomal complex
was associated with silencing of pseudoexon splicing of
growth hormone receptor. Moreover, mitogenic stimula-
tion promotes Pak1- and PCBP1-dependent alternative
splicing and exon inclusion from a CD44 minigene. The
alternative splicing functions of PCBP1 are in turn medi-
ated by its intrinsic interaction with Caper alpha, a U2
snRNP auxiliary factor-related protein previously impli-
cated in RNA splicing. Furthermore, another hnRNP
family member hnRNP A1 was a component of an exon-
specific splice-silencing complex, and transient overex-
pression of hnRNP A1 prevented v6 splicing. These
results indicate that PCBP1 might be a trans-acting factor
in silencing of mRNA splicing just like hnRNP A1 does.
In our present study, we confirmed that PCBP1 inhibits
CD44 variant splicing including v5 and v6 and knock-
down of endogenous PCBP1 stimulates the CD44 vari-
ants splicing, suggesting that PCBP1 is a novel negative
regulator of CD44 variants splicing. However, in a previ-
ous study [15], a positive role of PCBP1 in CD44 v5 splic-
ing was detected. This difference might be due to the
different cell lines used and a phosphorylation of PCBP1
by Pak-1 in the presence of EGF in their cell models.
Variant CD44 isoforms are involved in a variety of
physiological and pathological processes, among which
tumor progression has received most attention. During
the past decade, a vast number of primary tumors and
metastases from close to 10,000 patients have been
screened for the expression of CD44 v6. This expression
pattern has made CD44v6 an attractive target for anti-
body-guided therapy of various types of cancers [16]. Our
data in the present study suggest a novel function of
PCBP1 in the regulation of CD44 v6 splicing. Previous
studies suggest that the activation of Ras/MAPK signal-
ing induced by HGF initiates a positive feedback loop by
stimulating isoform-specific CD44 expression through
alternative splicing. This positive feedback loop plays a
key role in the transition from normal to transformed
phenotypes. PCBP1 could inhibit the v6 expression
induced by Ras activation and HGF and then break the
positive feedback loop, suggesting that PCBP1 might
function as a candidate tumor suppressor and play a
potential role in the gene therapy of malignant tumors
with v6 overexpression. Furthermore, we demonstrate
the association between up-regulation of v6 and down-
regulation of PCBP1 in primary HCC patients, which
raises the possibility that v6 overexpression in liver can-
cer may be partly due to the down-regulation of PCBP1.
Consistent with these observations, overexpression of
PCBP1 in HepG2 cells dramatically inhibits the v6
expression and tumor invasion while re-expression of v6
reverses the effect of PCBP1 in cell invasion. Thus, it is
possible that PCBP1 regulates the cell invasion partly
through regulating the CD44 v6 expression level.
Interestingly, our data suggest that PCBP1 regulates the
CD44 alternative splicing in an exon-specific manner.
PCBP1 inhibits the splicing of v3, v5, v6, v7 and v8, while
has no effect on v9, and standard form of CD44. PCBP1
has three KH domains and the first and the second KH
domains can independently bind poly(rC) with a high
affinity and specificity [17]. So it seems that PCBP1 regu-
lates the CD44 alternative splicing by binding to mRNA
directly. However, sequence comparison of the CD44
variant exon v3 through v8 revealed no obvious common
exon silencing elements or the consensus sequence bind-
ing to PCBP1, indicating that PCBP1, possibly in associa-
tion with other partner proteins, through an exon-
specific combination of distinct mall sequence elements
in a cooperative manner. Recently, hnRNP proteins have
Figure 5 Negative Correlation of PCBP1 and CD44 v6 mRNA ex-
pression in HCC tissue samples analyzed. Total RNA was extracted 
from HCC specimens and their adjacent non-cancerous liver tissues for 
real-time PCR analysis. The expression levels of PCBP1, v6 and std in 
non-cancerous tissues were set to 1 and normalized to GAPDH mRNA. 
The experiments in each sample were performed in triplicate with at 
least 3 independent times. The data was shown as the average of these 
experiments. Then Spearman test was performed.Zhang et al. Molecular Cancer 2010, 9:72
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been shown to hinder communication between factors
bound to different splice sites. Moreover, cooperative
interactions between bound hnRNP proteins may
encourage splicing between specific pairs of splice sites
while simultaneously hampering other combinations.
Thus, hnRNP proteins utilize a variety of strategies to
control splice site selection in a manner that is important
for alternative pre-mRNA splicing [18]. Further identifi-
cation of PCBP1 binding partners may facilitate under-
standing of the mechanism of PCBP1 in selectively
regulating mRNA splicing.
Although the functions of PCBPs in alternative mRNA
splicing, translation silencing and transcriptional regula-
tion have been widely reported, only a few studies suggest
that PCBP1 might play a role in tumor invasion. In a pre-
vious study, analysis of PCBP1 expression in different
grade squamous intraepithelial lesions, and invasive cer-
vical carcinoma showed that PCBP1 expression
decreased in high grade squamous intraepithelial lesions
and cancer, respectively and the loss of PCBP1 expression
may allow HPV infected cervical tissues to undergo virus
mediated transformation from cervical dysplasia to can-
cer [19]. Various studies have suggested that several other
members of the hnRNP family associate with tumor. The
pre-mRNA processing protein, hnRNP A2/B1, has been
proposed as a promising biomarker for lung cancer [20].
The overexpression of hnRNP C1/C2 was demonstrated
in HCC samples, suggesting their potential as protein
tumor markers [21]. In addition, hnRNP F is down-regu-
lated in HCC and up-regulated in gastric carcinoma,
indicating the important while complex potential role of
this subset of hnRNPs on the gene expression in different
tissues [22]. Furthermore, the PCBP1 gene maps to
human chromosome 2 (2p13-12) which is one of the most
frequently altered region in human malignancies. Pesti et
al also delineated this region as a tumor suppressor gene
region [23]. In the present study, we provide convincing
evidence that PCBP1 is a negative regulator of cell inva-
sion in HepG2 cells.
Conclusions
Taken together, our present study suggests a negative role
of PCBP1 in CD44 variants splicing and cell invasion in
HepG2 cells, which raises the possibility that down-regu-
lation of PCBP1 might be a biomarker in tumor metasta-
sis.
Methods
Tissue specimens
All human hepatocellular carcinoma (HCC) specimens
were obtained from those patients who underwent surgi-
cal resection of their diseases and were informed consent
before operation on their liver. The primary tumor speci-
mens were immediately frozen at -80°C until RNA extrac-
tion. Both tumor and adjacent nontumor tissues were
sampled respectively, with approximate 1 cm3 size of each
specimen, and were proved by pathological examination.
This study was approved by the ethics committee at the
Beijing Institute of Radiation Medicine,
Cells and transfection
Human hepatoma cell lines HepG2 and SMMC-7721
cells were purchased from the Cell Institute of Chinese
Academy of Science (Shanghai, China) and maintained in
Dulbecco's modified Eagle's medium (Gibco) supple-
mented with 10% fetal bovine serum (Hyclone) at 37°C in
5% humidified CO2. DNA transfection was carried out
using Lipofectamine2000 (Invitrogen, Carlsbad, CA,
USA) as a mediator according to the manufacturer's
instruction.
Plasmid constructions
The human full-length PCBP1 were amplified by PCR
from the human liver cDNA and cloned into the
pcDNA3.1 (His/Myc) vector (Invitrogen, Carlsbad, CA,
USA). pETCatEBlucv5 was kindly provided by Prof. Weg-
Remers S (Forschungszentrum Karlsruhe der Helmholtz-
Gemeinschaft, Institut für Toxikologie und Genetik,
Karlsruhe, Germany) The constitutive activation H-Ras
V12 construct was kindly provided by Dr. Herb Sun
(Mount Sinai School of Medicine, New York, USA). The
sequences of the primers are provided in Table S1; Addi-
tional file 2.
RNA interference (RNAi)
The small interfering RNA (siRNA) oligos of PCBP1 were
synthesized in GenePharma Biotechnology, the
sequences are as follows: si-PCBP1-1, sense: CAC CAU
UCC AAA UAA CUU ATT; antiense: UAA GUU AUU
UGG AAU GGU GAG; si-PCBP1-2, sense: GAA CCA
GGU GGC AAG ACA ATT; antisense: UUG UCU UGC
CAC CUG GUU CAG. The sequence of CD44 v6 siRNA
oligos are: si-v6-1, sense: UGA GGG AUA UCG CCA
AAC ATT; antisense: UGU UUG GCG AUA UCC CUC
ATT; si-v6-2, sense: GCA ACU CCU AGU AGU ACA
ATT; antisense: UUG UAC UAC UAG GAG UUG CTT.
The negative control siRNA (N.C) was obtained from
Qiagen (Qiagen, Germantown, MD, USA). Another nega-
tive control siRNA (N.C-2) was obtained from GenePh-
arma (GenePharma, Shanghai, China) with different
sequence from N.C: sense: UUC UCC GAA CGU GUC
ACG UTT; antisense: ACG UGA CAC GUU CGG AGA
ATT. siRNA oligos were transfected into HepG2 cells
using Lipofectamine 2000 (Invitrogen) at a concentration
of 20 nM.
Transfection and luciferase assay
Cells were plated in 24-well tissue culture plate at a den-
sity of 5 × 104cell per well and transfected with 0.5 μg of
each construct reporter plasmid. As an internal control,
the pRL-TK vector was cotransfected which led to theZhang et al. Molecular Cancer 2010, 9:72
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constitutive expression of Rennila  luciferase (Promega
Corp., Madison, WI, USA). Twenty four hours after
transfection, luciferase activity was measured with the
Dual Luciferase Assay system (Promega) according to the
manufacturer's instructions. Briefly, the cells were lysed
directly in the 24-well plate using 100 μl of 1 × passive
lysis buffer provided with the Dual-Luciferase kit. One
hundred microliters of LARII reagent (firefly luciferase
substrate) was added to 50 μl of lysis supernatant, and
firefly luciferase activity was measured with a chemilumi-
nescence analyzer (FB12 luminometer; Berthold Detec-
tion Systems, Montreal Biotech Inc., CA, USA) for 10 s.
Then, 100 μl of Stop-n-Glo reagent (Renilla  luciferase
substrate) was added to the reaction, and Renilla
luciferase activity was measured for an additional 10 s.
Firefly luciferase activities were normalized by Renilla
activities to correct for differences in transfection effi-
ciencies. All transfection and reporter assays were per-
formed independently at least three times. Firefly
luciferase activities normalized by Renilla activities are
presented as fold induction relative to the normalized
firefly luciferase activity in cells transfected with empty
vector only or negative control siRNA oligos, which was
taken as 100% or 1.0.
Reverse transcription-PCR (RT-PCR) and quantitative real-
time RT-PCR
Total RNA was reverse-transcribed and amplified using
reverse transcription (RT; Promega) and PCR (Promega)
kits, respectively. The PCR products were electrophore-
sed on 1% agarose gels and photographed under ultravio-
let light. Quantity One software (BioRad, USA) was used
for densitometry analysis. Quantitative real-time RT-
PCR was done by ABI Prism 7700 Sequence Detector
(Applied Biosystems, Foster City, CA). The abundance of
mRNA of each gene was normalized to the amount of
total RNA. The sequences of the primers are provided in
Table S1; Additional file 2.
Western blotting
For Western blotting, cells were lysed with M-PER® Mam-
malian Protein Extraction Reagent (Pierce, Rockford, IL).
Then, Western blot analysis was performed according to
standard procedures. Antibodies were used at the follow-
ing concentrations: anti-Myc, 1:500 (Santa Cruz Biotech-
nology, Santa Cruz, CA; anti-PCBP1, 1:500 (Santa Cruz)
and anti-β-actin (sc-47778, Santa Cruz), 1:1000. Chemi-
luminescent detection was conducted using supersignal
substrate, according to the manufacturer's specifications.
Matrigel invasion assay
Biocoat Matrigel invasion chambers (Becton Dickinson)
were used to assess the invasiveness of HepG2 cells. 5 ×
104  cells were resuspended in 250 μl of serum-free
DMEM and added to the cell culture inserts of the inva-
sion chambers. Fetal bovine serum (10%) was used as a
chemoattractant and placed in the lower wells. After 22
to 24 h, cells on the upper surface of the membrane were
removed using cotton swabs, and the filters were fixed by
immersion in 4% formaldehyde for 10 min. After two
washes with water, the invaded cells were then stained
with 0.2% crystal violet. Excess dye was rinsed off two
times with water. The number of cells that had migrated
to the lower surface of the filter membrane was counted
in five randomly chosen fields under a light microscope
Statistical Analysis
All experiments were performed at least three times.
Data were reported as means ± SD and a value of p ≤ 0.05
was considered to be statistically significant. Students-
Newman-Keuls tests were used to analyze comparisons
between groups. The Spearman correlation test was used
to analyze the correlation between parameters.
Additional material
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